Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

219
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In vitro</i> pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against <i>Mycobacterium tuberculosis</i>.

Frontiers in microbiology·2026
Same author

<i>In vitro</i> characterization of GSK2556286 in combination with bedaquiline and pretomanid against <i>Mycobacterium tuberculosis</i>.

Antimicrobial agents and chemotherapy·2026
Same author

Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.

The Lancet. Infectious diseases·2026
Same author

Five years of national airborne pollen monitoring in South Africa: biome-specific calendars to inform allergy diagnosis and prevention.

Aerobiologia·2026
Same author

Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis.

Antimicrobial agents and chemotherapy·2026
Same author

Climate Change And Its Impact On Asthma In South Africa.

Current allergy & clinical immunology·2026

Related Experiment Video

Updated: Aug 1, 2025

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.5K

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug

Laurynas Mockeliunas1, Alan Faraj1, Rob C van Wijk1

  • 1Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Frontiers in Pharmacology
|May 1, 2023
PubMed
Summary

A new pharmacometric model standardizes early bactericidal activity (EBA) analysis for tuberculosis drug development. This approach optimizes sample sizes for Phase 2a trials, improving the detection of drug efficacy and treatment differences.

Keywords:
early bactericidal activitymodel-based analysispharmacometricssample sizetuberculosis

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Related Experiment Videos

Last Updated: Aug 1, 2025

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.5K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Area of Science:

  • Pharmacometrics
  • Tuberculosis Drug Development
  • Clinical Trial Design

Background:

  • Phase 2a early bactericidal activity (EBA) studies are crucial for assessing new tuberculosis (TB) drug efficacy in humans.
  • Standardized analysis is needed to reliably interpret EBA data and inform go/no-go decisions in TB drug development.

Purpose of the Study:

  • To present a standardized pharmacometric model-based workflow for EBA analysis.
  • To determine optimal sample sizes for detecting EBA and treatment differences in Phase 2a trials.

Main Methods:

  • Developed a seven-step standardized pharmacometric model-based EBA analysis approach.
  • Applied non-linear mixed effects modeling to explore sample size calculations under various scenarios.
  • Assessed sample sizes needed to detect EBA and differences between treatment arms, considering TTP slope and variability.

Main Results:

  • The model estimates EBA with uncertainty, incorporating TTP slope, variability, covariates, and pharmacokinetics.
  • Sample sizes of 13 and 8 participants/arm are sufficient to detect EBA with 80% power under specific conditions.
  • Accounting for pharmacokinetics and variability is essential for accurate sample size determination in EBA studies.

Conclusions:

  • A robust, standardized pharmacometric model-based EBA analysis approach was established.
  • The approach enhances the power to detect EBA and treatment differences in Phase 2a TB drug development trials.
  • Accounting for covariates and drug exposure is vital for increasing the sensitivity of EBA analyses.